Fundraising FoxLongwood Fund — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundRidgeback CapitalSR One Capital Management+4 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capitalabrdn plc+4 more
Anuncia Medical develops medical technology focused on cerebrospinal fluid (CSF) science and clinical strategy to advance hydrocephalus treatment.
BiotechHealthtechMedical DevicesScottsdale, US
Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)in
BoardEdgar D Janotta(Director)Stanton Rowe(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
Co-investorsArieal Southeast Angel PartnersXcellerant Ventures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalBiotechnology Value Fund+2 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersDolby Family VenturesMission BiocapitalService Provider CapitalForbion
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.